中国药业2025，Vol.34Issue(21)：1-7,7.DOI:10.3969/j.issn.1006-4931.2025.21.001
预混胰岛素临床综合评价专家共识
Expert Consensus on Clinical Comprehensive Evaluation of Premixed Insulin
摘要
Abstract
Objective To provide a reference for clinical selection and rational use of premixed insulin in medical institutions.Methods A total of 30 pharmaceutical experts from six tertiary hospitals in different provinces and cities in our country were invited,and the expert consultation method was adopted.After three rounds of expert opinion survey and discussion,the Expert Consensus on Clinical Comprehensive Evaluation of Premixed Insulin was formed.A total of 23 premixed insulins from the sixth batch of the National Centralized Drug-Procurement Program(referred to as national centralized procurement)were selected for clinical comprehensive evaluation.Results Comprehensive clinical evaluation indexes and scoring criteria for premixed insulin were formulated from six dimensions:effectiveness,safety,economy,suitability,accessibility,and innovation.The clinical comprehensive evaluation results showed that the top three in terms of the comprehensive score of the sixth batch of the national centralized procurement(premixed insulin)were Novolin® 30R,NovoMix® 30,and Novolin® 50R,but the top three in terms of the sum of effectiveness and economy scores were USLIN® 50R,Ganshulin 50R,and Novolin® 50R.Conclusion The formulation of this consensus provides a reference for the clinical comprehensive evaluation of premixed insulin,the formulation of drug allocation and procurement catalogs in medical institutions,and the adjustment of agreed procurement quantities for national centralized procurement.关键词
预混胰岛素/临床综合评价/药品遴选/专家共识Key words
premixed insulin/clinical comprehensive evaluation/drug selection/expert consensus分类
医药卫生引用本文复制引用
《预混胰岛素临床综合评价专家共识》专家组,马冰洁,苍爱军,王雨,郭琪,李佳..预混胰岛素临床综合评价专家共识[J].中国药业,2025,34(21):1-7,7.基金项目
中国医药教育协会《药事管理模式创新与药物临床综合评价研究》专项课题[2022ZXKT01]. （）
